

2-14-00

A

02/11/00
JCS88 U.S. PTO

09/502945
02/11/00
JCS88 U.S. PTO

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

L0461/7081

First Named Inventor or Application Identifier

Scanlan et al.

Express Mail Label No.

EL024661754US

Date of Deposit

February 11, 2000

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS

Assistant Commissioner for Patents

TO:

Box Patent Application
Washington, DC 20231

- 1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
- 2. ☒ Specification [Total pages 29]
 - 16 pages description
 - 1 page abstract
 - 12 pages claims
 - 56 claims
- 3. Drawing(s) (35 USC 113) [Total sheets ☐
☐ Informal ☐ Formal [Total drawings ☐
- 4. ☒ Oath or Declaration [Total pages 3]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
- 5. ☒ Incorporation by Reference
(usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

- 6. ☐ Microfiche Computer Program (Appendix)
- 7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Copy (see "other" below)
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8. ☐ Assignment Papers (cover sheet & documents(s))
- 9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
- 10. ☐ English Translation of Document (if applicable)
- 11. ☒ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
- 12. ☒ Preliminary Amendment
- 13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 14. ☐ Small Entity ☐ Statement filed in prior
Statement(s) application, Status still proper
and desired
- 15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. **Other:** Associate Power of Attorney; Letter requesting use of previous computer readable form; copy of computer disk label from previous case.

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:


☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/948,705

☒ Cancel in this application original claims 1-5, 7-36 and 41-56 of the prior application before calculating the filing fee.

☒ Amend the specification by inserting before the first line the sentence:

This application is a divisional of application serial no. 08/948,705, filed October 10, 1997, entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, and now pending.

18. CORRESPONDENCE ADDRESS					
Correspondence address below					
ATTORNEY'S NAME	John R. Van Amsterdam, Reg. No. 40,212				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	
DATE	FEBRUARY 11, 2000

0950294661754US

Attorney's Docket No. **L0461/7081**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Scanlan et al.
Serial No: Unknown
Filed: Herewith
For: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON
CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON
CANCER
Examiner: Not Assigned
Art Unit: Unknown

Box Patent Application
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please enter this Preliminary Amendment as follows:

In the Specification

On page 4, line 12, please delete "Applications Serial".

On page 4, lines 13-14, please delete "08/580,980 , and Application Serial No.
08/479,328, filed on June 7, 1995 and January 3, 1996, respectively" and insert --5,698,396--
therefor.

On page 4, line 14, please delete "All three" and insert --Both-- therefor.

On page 6, line 5, please delete "with the IgG then interacting".

On page 6, line 19, please delete "allowed U.S. Patent Application Serial No.
08/479,328" and insert --U.S. Patent 5,698,396-- therefor.

On page 9, line 18, please delete "300-400" and insert --300 to 400-- therefor.

On page 10, line 1, please delete "screening" and insert --screened-- therefor.

On page 10, line 20, please delete "breain" and insert --brain-- therefor.

On page 11, line 2, please delete "wherein," and insert --, wherein-- therefor.

In the Claims

Please cancel without prejudice claims 1-5, 7-36 and 41-56.

Please amend the claims as follows:

6.(amended) An [I]isolated protein encoded by [the] an isolated nucleic acid [of claim 1] molecule selected from the group consisting of:

(a) nucleic acid molecules which encode a cancer associated antigen, and which comprise a nucleotide sequence, the complementary sequence of which hybridizes, under stringent conditions, to at least one second nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the nucleotide sequences set forth as SEQ ID NOs: 1, 2, 3, 4, and 5,

(b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and

(c) complements of (a) or (b).

37.(amended) A composition of matter useful in stimulating an immune response to at least one protein encoded by at least one nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, said composition comprising a plurality of peptides derived from the amino acid sequence of said at least one protein, wherein said peptides bind to one or more MHC molecules presented on the surface of cells which express an abnormal amount of said at least one protein.

Please add the following new claims:

57. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:1.

58. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:2.

59. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:3.


60. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:4.
61. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:5.
62. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:1.
63. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:2.
64. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:3.
65. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:4.
66. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:5.
67. The composition of matter of claim 37, wherein at least one of the plurality of peptides is coupled to an immune response stimulating compound.

REMARKS

Please enter this Preliminary Amendment before calculating the fees. Applicants have deleted all claims but those corresponding to claim group number 2 (claims 6 and 37-40) as set forth in the restriction requirement mailed on October 1, 1998 in the parent case, serial number 08/948,705. Amendments to the Specification are the same as made in the parent application.

New claims 57-61 and 62-66 are derived from original claims 6 and 37, respectively. Support for new claim 67 can be found in the Specification at page 14, line 16. No new matter has been added.

Respectfully submitted,



John R. Van Amsterdam

Reg. No. 40,212

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue

Boston, MA 02210

Tel. (617)720-3500

ATTORNEY DOCKET NO. L0461/7081

Date: February 17, 2000

xNDD

00720 3500

Table 1. Demographic characteristics of the study population	
Age (years)	Mean (SD)
Male	55.2 (10.5)
Female	56.8 (11.2)
Marital status	
Married	78.5%
Single	21.5%
Education level	
High school or above	65.2%
Below high school	34.8%
Occupation	
Professional	12.3%
Managerial	18.7%
Technical	25.4%
Service	32.1%
Unemployed	11.5%
Income (USD/month)	
< 1000	15.2%
1000-2000	28.7%
2000-3000	35.4%
> 3000	20.7%
Health insurance	
Yes	89.1%
No	10.9%
Smoking status	
Smoker	22.3%
Non-smoker	77.7%
Alcohol consumption	
Regular	8.5%
Occasional	15.2%
Never	76.3%
Family size	
1-2	32.1%
3-4	45.7%
5 or more	22.2%

FIELD OF THE INVENTION

This invention relates to the isolation of genes associated with colon cancer, methods of diagnosing colon cancer using these, as well as other genes which are known, as well as therapeutic approaches to treating such conditions.

BACKGROUND AND PRIOR ART

It is fairly well established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc., are characterized by the inappropriate expression of certain molecules. These molecules thus serve as "markers" for a particular pathological or abnormal condition. Apart from their use as diagnostic "targets", i.e., materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents. A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker. Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells.

Preparation of such materials, of course, presupposes a source of the reagents used to generate these. Purification from cells is one laborious, far from sure method of doing so. Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule.

To date, two strategies have been employed for the detection of such antigens, in e.g., human tumors. These will be referred to as the genetic approach and the biochemical

approach. The genetic approach is exemplified by, e.g., dePlaen et al., Proc. Natl. Sci. USA 85: 2275 (1988), incorporated by reference. In this approach, several hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negative variants of tumor cell lines. Transfectants are screened for the expression of tumor antigens via their ability to provoke reactions by anti-tumor cytolytic T cell clones. The biochemical approach, exemplified by, e.g., Mandelboim, et al., Nature 369: 69 (1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromatography (HPLC). Antigenic peptides are identified after they bind to empty MHC-class I molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytolytic T-lymphocytes ("CTLs"). These reactions include induction of CTL proliferation, TNF release, and lysis of target cells, measurable in an MTT assay, or a ^{51}Cr release assay.

These two approaches to the molecular definition of antigens have the following disadvantages: first, they are enormously cumbersome, time-consuming and expensive; second, they depend on the establishment of CTLs with predefined specificity; and third, their relevance in vivo for the course of the pathology of disease in question has not been proven, as the respective CTLs can be obtained not only from patients with the respective disease, but also from healthy individuals, depending on their T cell repertoire.

The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods have, so far, succeeded in defining only very few new antigens in human tumors. See, e.g., van der

Bruggen et al., Science 254: 1643-1647 (1991); Brichard et al., J. Exp. Med. 178: 489-495 (1993); Coulie, et al., J. Exp. Med. 180: 35-42 (1994); Kawakami, et al., Proc. Natl. Acad. Sci. USA 91: 3515-3519 (1994).

Further, the methodologies described rely on the availability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by, e.g., Oettgen, et al., Immunol. Allerg. Clin. North. Am. 10: 607-637 (1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs in vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens.

One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. Patent Applications Serial No. 08/580,980, and Application Serial No. 08/479,328, filed on June 7, 1995 and January 3, 1996, respectively. All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immunoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method ("Serological identification of antigens by Recombinant Expression Cloning"). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144: 2333-2340

(1995).

The SEREX methodology has now been applied to colon cancer samples. Several nucleic acid molecules have been newly isolated and sequenced, and are now associated with stomach cancer. Further, a pattern of expression involving these, as well as previously isolated genes has been found to be associated with colon cancer. These results are the subject of this application, which is elaborated upon in the disclosure which follows.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Example 1

Tumor samples were obtained as surgical samples, and were frozen at -80°C until ready for use.

Total RNA was then isolated from the samples, using the well known guanidium thiocyanate method of Chirgwin, et al., Biochemistry 18: 5294-5299 (1979), incorporated by reference. The thus obtained total RNA was then purified to isolate all poly A⁺ RNA, using commercially available products designed for this purpose.

The poly A⁺ RNA was then converted into cDNA, and ligated into λZAP, a well known expression vector.

Three cDNA libraries were constructed in this way, using colorectal carcinoma samples. A fourth library, also from colorectal carcinoma, was prepared, albeit in a different way. The reasons for this difference will be clear in the examples, infra.

The fourth library was an IgG subtraction library, prepared by using a subtraction partner, generated by PCR amplification of a cDNA clone which encoded an IgG molecule.

See, e.g., Ace et al, Endocrinology 134: 1305-1309 (1994), and incorporated by reference in its entirety.

This is done to eliminate any false, positive signals resulting from interaction of cDNA clones which encode IgG, with the IgG then interacting with the anti-human IgG used in the assay, as described infra. PCR product was biotinylated, and hybridized with denatured second strand cDNA, at 68°C for 18 hours. Biotinylated hybrid molecules were coupled to streptavidin, and then removed by phenol chloroform extraction. Any remaining cDNA was also ligated into λZAP. All libraries were amplified, prior to immunoscreening discussed infra.

Example 2

Immunoscreening was carried out, using sera obtained from patients undergoing routine diagnostic and therapeutic procedures. The sera were stored at -70°C prior to use. Upon thawing, the sera were diluted at 1:10 in Tris buffered saline (pH 7.5), and were then passed through Sepharose 4B columns. First, the sera were passed through columns which had E. coli Y1090 lysates coupled thereto, and then lysates from bacteriophage infected E. coli BNN97 lysates. Final serum dilutions were then prepared in 0.2% non-fat dried milk/Tris buffered saline.

The method of Sahin et al., Proc. Natl. Acad. Sci. USA 92: 11810-11813 (1995), and allowed U.S. patent application Serial No. 08/479,328, both of which are incorporated by reference, was used, with some modifications. Specifically recombinant phage at a concentration of 4×10^3 phages per 15 cm plate (pfus), were amplified for six hours, after

which they were transferred to nitrocellulose membranes for 15 hours. Then, the membranes were blocked with 5% nonfat dried milk.

As an alternative to the IgG subtraction, discussed supra, membranes were prescreened in a 1:2000 dilution of peroxidase conjugated, Fc fragment specific goat anti-human IgG, for one hour, at room temperature. Color was developed using 3,3-diaminobenzidine tetrahydrochloride, which permitted scoring of IgG encoding clones.

Membranes were then incubated in 1:100 dilutions of autologous sera, which had been pretreated with the Sepharose 4B columns, as described supra. The filters were then incubated, in a 1:3000 dilution of alkaline phosphatase conjugated Fc fragment specific, goat anti-human IgG, for one hour, at room temperature. The indicator system 4-nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate was then added, and color development assessed. Any positive clones were subcloned, and retested, except the time on the nitrocellulose membrane was reduced to three hours. A total of forty-eight positive clones were identified.

Analysis of probes for SEQ ID NOS: 1 and 2 confirmed their universal expression.

Example 3

Example 2 described work using autologous serum. The positive clones were then rescreened, using allogeneic serum, following the same method discussed supra, in example 2, except IgG prescreening was omitted. The allogeneic sera was obtained from sixteen normal blood donors, and twenty nine patients who had been diagnosed with colorectal cancer.

The analysis with the two types of serum revealed that fourteen reacted with a subset of sera from normal and cancer patients, twenty-eight only with autologous sera, and six with both allogeneic and autologous sera. Over 60% of the allogeneic serum samples tested reacted with at least one of these positive clones. About 20% reacted with two or more.

5 Example 4

In view of the results described in example 3, further experiments were carried out using serum samples from patients with other forms of cancer, i.e., renal cancer (13 samples), lung cancer (23 samples), and breast cancer (10 samples). The results are set forth in Table I which follow:

Clone Number	Normal Sera	Colon Cancer	Renal Cancer	Lung Cancer	Breast Cancer
NY-Co-8	0/16	8/29	1/13	0/23	0/10
NY-Co-9	0/16	5/29	1/13	1/23	0/10
NY-Co-13	0/16	5/29	0/13	0/23	0/10
NY-Co-16	0/16	3/29	0/13	0/23	0/10
NY-Co-20	0/16	4/29	0/13	0/23	0/10
NY-Co-38	0/16	4/29	3/13	0/23	1/10

Example 5

Following the screening work described supra, the cDNA inserts were purified and sequenced, following standard methods.

Of the six clones which were identified as being reactive with autologous and allogeneic cancer serum, and not with normal serum, two were found to be identical to previously identified molecules. Four others were found to have little or no homology to known sequences. These are presented as SEQ ID NOS: 1-4. Of twenty seven allogeneic colon cancer serum samples tested, 67% reacted with at least one of these antigens.

Example 6

The expression pattern of mRNA corresponding to SEQ ID NOS: 1, 2 and 4, as well as other sequences identified via the preceding examples was determined. To do this, RT-PCR was carried out on a panel of RNA samples, taken from normal tissue. The panel contained RNA of lung, testis, small intestine, colon, breast, liver and placenta tissues. The RNA was purchased from a commercial source. RNA from a colon tumor sample was also included. All samples were set up for duplicate runs, so that genomic DNA contamination could be accounted for. In the controls, no reverse transcriptase was used.

Primers were designed which were specific for the cDNA, which would amplify 5'-fragments, from 300-400 base pairs in length. The PCR reactions were undertaken at an annealing temperature of 68°C. Where appropriate, 5' and 3'-RACE reactions were undertaken, using gene specific primers, and adapter primers, together with commercially available reagents. Specifically, SEQ ID NOS: 2 and 4 were tested using RACE. The

resulting products were subcloned into vector pCR 2.1, screening via PCR using internal primers, and then sequenced.

SEQ ID NOS: 1 and 2 were found to be amplified in all tissues tested. SEQ ID NO: 4 was found in colon tumor, colon metastasis, gastric cancer, renal cancer and colon cancer cell lines Colo 204 and HT29, as well as in normal colon, small intestine, brain, stomach, testis, pancreas, liver, lung, heart, fetal brain, mammary gland, bladder, adrenal gland tissues. It is was not found in normal uterine, skeletal muscle, peripheral blood lymphocytes, placental, spleen thymus, or esophagus tissue, nor in lung cancer.

The analysis also identified differential expression of a splice variant of SEQ ID NO: 4, i.e., SEQ ID NO: 5. When the two sequences were compared, it was found that SEQ ID NO: 4 encodes a putative protein of 652 amino acids, and molecular weight of 73,337 daltons. SEQ ID NO: 5, in contrast, lacks an internal 74 base pairs, corresponding to nucleotides 1307-1380 of SEQ ID NO: 4. The deletion results in formation of a stop codon at the splice function, and a putative protein of 404 amino acids, and molecular weight 45,839. The missing segment results in the putative protein lacking a PEST protein degradation sequence, thereby suggesting a longer half life for this protein.

In additional experiments, primers designed not to differentiate between SEQ ID NOS: 4 and 5 resulted in almost universal amplification (placenta being the only exception). In contrast, when primers specific for SEQ ID NO: 5 were used differences were seen in normal pancreatic, liver, lung, heart, fetal breain, mammary gland, bladder, and adrenal gland tissue, where there was no expression of SEQ ID NO: 5 found.

Example 7

Northern blotting was also carried out for SEQ ID NOS: 1, 2, 4 and 5. To do this, the same commercially available RNA libraries discussed supra were used.

Samples (2 ug) of polyA⁺ RNA were analyzed from these samples, using random, ³²P labelled probes 300-360 nucleotides in length, obtained from PCR products. These probes were hybridized to the RNA, for 1.5 hours, at 68°C, followed by two washes at 0.1xSSC, 0.1% SDS, 68°C, for 30 minutes each time.

SEQ ID NOS: 1 and 2 were again found to be universally expressed.

Example 8

Further screening identified additional isoforms of SEQ ID NOS: 1 and 4. These are set forth as SEQ ID NOS: 6, 7 and 8. The isoform represented by SEQ ID NO: 6 is a naturally occurring splice variant of SEQ ID NO: 1, found in normal colon. SEQ ID NO: 7, which is an isoform of SEQ ID NO: 4, was found in brain tissue, primarily spinal chord and medulla. SEQ ID NO: 8, was found in normal kidney and in colon tumors, metastasized colon cancer, gastric cancer, and in colon cancer cell line Colo 205. It was not found in any normal tissue other than kidney.

The foregoing examples demonstrate several features of the invention. These include diagnostic methods for determining presence of transformed cells, such as colon cancer cells, in a sample. The sample may contain whole cells or it may be, e.g., a body fluid sample, or an effusion, etc., where the sample may contain cells, but generally will contain shed antigen. The experiments indicate that there is a family of proteins, expression of which is

associated with colon cancer. Hence, the invention involves, inter alia, detecting at least two of the proteins encoded by any of SEQ ID NOS: 1-5 wherein, presence of these is indicative of a pathology, such as colon cancer or other type of related condition. Exemplary of the type of diagnostic assays which can be carried out are immunoassays, amplification assays (e.g., PCR), or, what will be referred to herein as a "display array". "Display array" as used herein refers to a depiction of the protein profile of a given sample. Exemplary of such displays are 2-dimensional electrophoresis, banding patterns such as SDS-gels, and so forth. Thus, one aspect of the invention involves diagnosing colon cancer or a related condition by determining protein display of a sample, wherein a determination of at least one of the proteins, or expression of their genes, is indicative of colon cancer or a related condition. There are many ways to carry out these assays. For example, as indicated herein, antibodies to the proteins were found in patient samples. One can assay for these antibodies using, e.g., the methodology described herein, or by using a purified protein or proteins or antigenic fragment thereof, and so forth. One can also assay for the protein itself, using antibodies, which may be isolated from samples, or generated using the protein and standard techniques. This antibodies can then be labelled, if desired, and used in standard immunoassays. These antibodies or oligonucleotide probes/primers may also be used to examine biopsied tissue samples, e.g., to diagnose precancerous conditions, early stage cancers, and so forth.

Similarly, any and all nucleic acid hybridization systems can be used, including amplification assays, such as PCR, basic probe hybridization assays, and so forth. The antibodies, such as polyclonal antibodies, monoclonal antibodies, the hybridomas which

produce them, recombinantly produced antibodies, binding fragments of these, hybridization kits, DNA probes, and so forth, are all additional features of the invention.

Any of these assays can also be used in progression/regression studies. One can monitor the course of an abnormality such as colon cancer which involve expression of any one of the proteins, the expression of which is governed by the nucleic acid molecules SEQ ID NOS: 1-5, simply by monitoring levels of the protein, its expression, and so forth using any or all of the methods set forth supra.

As has been indicated supra, the isolated nucleic acid molecules which comprise the nucleotide sequences set forth in SEQ ID NOS: 1-5 are new, in that they have never been isolated before. These nucleic acid molecules may be used as a source to generate colon cancer specific proteins and peptides derived therefrom, and oligonucleotide probes which can themselves be used to detect expression of these genes. Hence, a further aspect of the invention is an isolated nucleic acid molecule which comprises any of the nucleotide sequences set forth in SEQ ID NOS: 1-5, or molecules whose complements hybridize to one or more of these nucleotide sequences, under stringent conditions, expression vectors comprising these molecules, operatively linked to promoters, cell lines and strains transformed or transfected with these, and so forth. "Stringent conditions", is used herein, refers to condition such as those specified in U.S. Patent No. 5,342,774, i.e., 18 hours of hybridization at 65°C, followed by four one hour washes at 2xSSC, 0.1% SDS, and a final wash at 0.2xSSC, more preferably 0.1xSSC, 0.1% SDS for 30 minutes, as well as alternate conditions which afford the same level of stringency, and more stringent conditions.

It should be clear that these methodologies may also be used to track the efficacy of a

therapeutic regime. Essentially, one can take a baseline value for the protein or proteins being tested, using any of the assays discussed supra, administer a given therapeutic, and then monitor levels of the protein or proteins thereafter, observing changes in protein levels as indicia of the efficacy of the regime.

5 The identification of the proteins and nucleic acid molecules set forth herein as being implicated in pathological conditions such as colon cancer also suggests a number of therapeutic approaches to such conditions. The experiments set forth supra establish that antibodies are produced in response to expression of these proteins, suggesting their use as a vaccine. Hence, a further embodiment of the invention is the treatment of conditions which are characterized by expression of one or more of the subject proteins, via immunotherapeutic approaches. One of these approaches is the administration of an amount of one or more these proteins, or an immunogenic peptide derived therefrom in an amount sufficient to provoke or augment an immune response. The proteins or peptides may be combined with one or more of the known immune adjuvants, such as saponins GM-CSF interleukins, and so forth. If the peptides are too small to generate a sufficient antibody response, they can be coupled to the well known conjugates used to stimulate responses.

 Similarly, the immunotherapeutic approaches include administering an amount of inhibiting antibodies sufficient to inhibit the protein or proteins. These antibodies may be, e.g., antibodies produced via any of the standard approaches elaborated upon supra.

20 T cell responses may also be elicited by using peptides derived from the proteins which then complex, non-covalently, with MHC molecules, thereby stimulating proliferation of cytolytic T cells against any such complexes in the subject. It is to be noted that the T

cells may also be elicited in vitro, and then reperfused into the subject being treated.

Note that the generation of T cells and/or antibodies can also be accomplished by administering cells, preferably treated to be rendered non-proliferative, which present relevant T cell or B cell epitopes for response.

5 The therapeutic approaches may also include gene therapies, wherein an antisense molecule, preferably from 10 to 100 nucleotides in length, is administered to the subject either "neat" or in a carrier, such as a liposome, to facilitate incorporation into a cell, followed by inhibition of expression of the protein. Such antisense sequences may also be incorporated into appropriate vaccines, such as in viral vectors (e.g., Vaccinia), bacterial constructs, such as variants of the well known BCG vaccine, and so forth.

10 An additional DNA based therapeutic approach is the use of a vector which comprises one or more nucleotide sequences, preferably a plurality of these, each of which encodes an immunoreactive peptide derived from the expressed proteins. One can combine these peptides expressing sequences in all possible variations, such as one from each protein, several from one or more protein and one from each of the additional proteins, a plurality
15 from some and none from others, and so forth.

Other features of the invention will be clear to the skilled artisan, and need not be repeated here.

20 The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions

-16-

We Claim:

1. An isolated nucleic acid molecule which comprises a nucleotide sequence, the complementary sequence of which hybridizes, under stringent conditions to at least one nucleic acid molecule having a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5.
2. Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.
3. Cell line or cell strain, transformed or transfected with the isolated nucleic acid molecule of claim 1.
4. Cell line or cell strain, transformed or transfected with the expression vector of claim 2.
5. The isolated nucleic acid molecule of claim 1, which consists of a nucleotide sequences set forth at SEQ ID NO: 1, 2, 3, 4 or 5.
6. Isolated protein encoded by the isolated nucleic acid molecule of claim 1.
7. Method for determining colon cancer in a sample, comprising assaying said sample for expression of the isolated nucleic acid molecule of claim 1, presence thereof being indicative of colon cancer.

8. Method for determining colon cancer in a sample, comprising assaying said sample for a protein encoded by the isolated nucleic acid molecule of claim 1, presence of said protein being indicative of colon cancer in said sample.

9. The method of claim 8, comprising assaying said sample for a peptide derived from said protein.

10. Composition of matter useful in treating colon cancer, comprising the isolated nucleic acid molecule of claim 1, and a pharmaceutically acceptable carrier.

11. Composition of matter useful in treating colon cancer, comprising therapeutically effective amount of the expression vector of claim 2, and a pharmaceutically acceptable carrier.

12. Composition of matter useful in treating colon cancer, comprising a therapeutically effective amount of the cell line or cell strain of claim 3, and having presented on its surface, a peptide complexed to an MHC molecule to form a complex which provokes an immune response against colon cancer cells.

13. A method for treating a subject afflicted with a colon cancer or related disorder, comprising:

(i) removing an immunoreactive cell containing sample from said subject,

(ii) contacting the immunoreactive cell containing sample to the cell line or cell strain of claim 3 conditions favoring production of cytolytic T cells against a peptide derived from the proteins encoded by the isolated nucleic acid molecule used to transfect or transform said cell, and

(iii) introducing said cytolytic T cells to said subject in an amount sufficient to lyse said cells.

14. A method for treating a subject afflicted with colon cancer or related condition, comprising:

(i) identifying a gene expressed by cancer cells associated with said colon cancer or related condition, wherein said gene comprises at least one nucleotide sequence set forth in SEQ ID NOS: 1-5;

(ii) identifying an MHC molecule which presents a portion of an expression product of said gene;

(iii) transfecting a host cell having the same molecule as identified in (ii) with said gene;

(iv) culturing said transfected cells to express said gene, and;

(v) introducing an amount of said cells to said subject sufficient to provoke an immune response against said cancer cells.

15. The method of claim 14, wherein said immune response comprises a B-cell response.

09502945, 021100

16. The method of claim 14, wherein said immune response comprises a T-cell response.

17. The method of claim 15, wherein said B cell response comprises production of antibodies specific to said expression product or peptide derived therefrom.

18. The method of claim 16, wherein said T-cell response comprises generation of cytolytic T-cell specific for cells presenting said peptide.

19. The method of claim 14, further comprising treating said cells to render them non-proliferative.

20. A method for treating a subject with a cancerous condition characterized by abnormal amounts of a protein, comprising:

(i) identifying a gene expressed by said abnormal cells, comprising at least one nucleotide sequence set forth in SEQ ID NOS: 1-5;

(ii) transfecting a host cell having the same MHC type as said patient expressing said gene;

(iii) culturing said transfected cells to express said gene, and;

(iv) introducing an amount of said cells to said subject sufficient to provoke an immune response against said cancerous condition.

21. The method of claim 20, further comprising treating said cells to render them non proliferative.

22. A method for treating a subject with a condition characterized by abnormal amounts of protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject an amount of a cell transfected with (i) a nucleic acid molecule which codes for said protein and (ii) a nucleic acid sequence which codes for an MHC molecule which presents a peptide derived from said protein wherein said peptide is presented by cells associated with said condition, sufficient to alleviate said condition.

23. Method of claim 22, further comprising treating said cell to render it non-proliferative.

24. A method for treating a subject afflicted with a condition characterized by an abnormal amount of protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject an amount of a reagent consisting essentially of non-proliferative cells having expressed on its surface a peptide characteristic of said abnormal cells in an amount sufficient to elicit an immune response thereto.

25. A method for treating a subject afflicted with a condition characterized by an abnormal amount of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject an antibody which specifically binds to said protein or a peptide derived therefrom, said antibody being coupled to a therapeutically useful agent, in an amount sufficient to treat said condition.

26. A method for treating a subject afflicted with a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject a sample of non-proliferative cells which express said protein in an amount sufficient to alleviate said condition.

27. A method for preventing onset of a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, in a subject comprising administering an amount of a vaccine comprising said protein and an adjuvant in an amount sufficient to prevent onset of said cancerous condition in said subject.

28. A method for preventing onset of a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, in a subject comprising administering an amount of a vaccine

comprising a peptide derived from said protein in an amount sufficient to prevent onset of said condition in said subject.

29. A method for preventing onset of a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, in a subject comprising administering an amount of a vector which comprises a gene encoding said protein to a cell which is capable of expressing said protein or presenting a peptide derived therefrom, in an amount sufficient to prevent onset of said cancerous condition in said subject.

30. A method for treating a subject afflicted with a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising:

- (i) identifying cells from said subject which express abnormal amounts of said protein;
- (ii) isolating a sample of said cells;
- (iii) cultivating said cell, and
- (iv) introducing said cells to said subject in an amount sufficient to provoke an immune response against said cells.

31. The method of claim 30, further comprising rendering said cells non proliferative, prior to introducing them to said subject.

32. A method for treating a subject with a condition characterized by abnormal amounts of at least one protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in any of SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject a vector which comprises a sequence encoding at least one immunoreactive peptide derived from said at least one protein, to a cell capable of expressing and presenting said at least one peptide, in an amount sufficient to induce an immune response in said subject.

33. A method for following progress of a therapeutic regime designed to alleviate a condition characterized by abnormal expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising:

(a) assaying a sample from a subject to determine level of a parameter selected from the group consisting of (i) a peptide derived from said protein, (ii) a cytolytic T cell specific for cells presenting said peptide, and (iii) an antibody which specifically binds to said peptide of said protein, at a first time period;

(b) assaying level of the parameter selected in (a) at a second period of time and comprising it to the level determined in (a) as a determination of effect of said therapeutic regime.

34. A method for treating a pathological cell condition characterized by aberrant expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5 associated with said condition, comprising

administering to a subject in need thereof an effective amount of either: (a) a protein inhibitor, or (b) an inhibitor of gene expression of said protein.

35. The method of claim 34, wherein said protein inhibitor is an inhibiting antibody.

36. The method of claim 34, wherein said inhibitor of gene expression is an antisense molecule.

37. A composition of matter useful in stimulating an immune response to a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, comprising a plurality of peptides derived from the amino acid sequence of said protein, wherein said peptides bind to one or more MHC molecules presented on the surface of cells which express an abnormal amount of said protein.

38. The composition of matter of claim 37, wherein at least a portion of said plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

39. The composition of matter of claim 38, further comprising an adjuvant.

40. The composition of matter of claim 39, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

41. An isolated antibody which binds to a protein encoded by a nucleic acid molecule which comprises the nucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4 or 5.

42. The isolated antibody of claim 41, wherein said antibody is a monoclonal antibody.

43. An isolated antibody which specifically binds to a peptide derived from a protein encoded by a nucleic acid molecule which comprises a nucleotide sequence set forth in any of SEQ ID NO: 1, 2, 3, 4 or 5.

44. The antibody of claim 43, wherein said antibody is a monoclonal antibody.

45. An isolated antibody which specifically binds to a complex of (i) a peptide derived from protein encoded by a nucleic acid molecule which comprises a nucleotide sequence set forth in any of SEQ ID NO: 1, 2, 3, 4 or 5 and (ii) an MHC molecule to which said peptide complexes, but does not bind to (i) or (ii) alone.

46. The antibody of claim 45, wherein said antibody is a monoclonal antibody.

47. Method for determining regression, progression or onset of a condition characterized by abnormal levels of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, comprising monitoring a

sample from a patient with said condition for a parameter selected from the group consisting of (i) protein, (ii) a peptide derived from said protein and (iii) cytolytic T cells specific for a peptide derived from said protein and an MHC molecule to which is bound is indicative of progression or regression or onset of said condition.

48. The method of claim 47, wherein said sample is a body fluid or effusion.

49. The method of claim 47, wherein said sample is a tissue.

50. The method of claim 47, wherein contacting said sample with an antibody which specifically binds with said protein or peptide.

51. The method of claim 50, wherein said antibody is labelled with a radioactive label or an enzyme.

52. The method of claim 50, wherein said antibody is a monoclonal antibody.

53. The method of claim 47, comprising amplifying RNA which codes for said protein.

54. The method of claim 53, wherein said amplifying comprises carrying out polymerase chain reaction.

55. The method of claim 47, comprising contacting said sample with a nucleic acid molecule which specifically hybridizes to a nucleic acid molecule which codes for or expresses said SCP protein.

56. The method of claim 47, comprising assaying said sample for said peptide.

00720" 64620560

Abstract Of The Disclosure

Various molecules associated with disorders such as colon cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.

LUD 5506-JEL/NDH

Express Mail Label No:

EL024661754US

Date of Deposit: 2-11-00

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, the specification of which

() is attached hereto.

(X) was filed on October 10, 1997 as Application Serial No. 08/948,705 and was amended on (1) _____, (2) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes ()	No ()
_____	_____	_____	_____	_____

(Number)	(Country)	(Day/Month/Year Filed)	Yes ()	No ()
_____	_____	_____	_____	_____

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
_____	_____	_____

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
_____	_____	_____

LUD 5506-JEL/NDH

Power of Attorney

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Norman D. Hanson, Reg. No. 30,946; Andrew L. Tiajolloff, Reg. No. 31,575; John A. Bauer, Reg. No. 32,554; Mary Anne Schofield, Reg. No. 36,669; Madeline F. Baer, Reg. No. 36,437 and James R. Crawford, Reg. No. 39,155, my attorneys with full power of substitution and revocation. Address all telephone calls to Norman D. Hanson, at (212) 688-9200. Address all correspondence to:

FELFE & LYNCH
805 Third Avenue
New York, New York 10022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Matthew J. Scanlan

Full Name/Sole or First Inventor Signature Date

Residence: 1275 York Avenue
New York, New York 10021

U.S.A.
Citizenship

Post Office Address: Memorial Sloan-Kettering Cancer Center
1275 York Avenue, New York, New York 10021

(2) Yao-Tseng Chen

Full Name/Second Inventor Signature Date

Residence: 525 East 68th Street
New York, New York 10021

Taiwan
Citizenship

Post Office Address: 525 East 68th Street
New York, New York 10021

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, the specification of which

() is attached hereto.

(X) was filed on October 10, 1997 as Application Serial No. 08/948,705 and was amended on (1) _____, (2) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	Yes () No ()
-------------------	--------------------	---------------------------------	----------------

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	Yes () No ()
-------------------	--------------------	---------------------------------	----------------

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

_____ (Applic. Serial No.)	_____ (Filing Date)	_____ (Status-patented/pending/abandoned)
-------------------------------	------------------------	--

_____ (Applic. Serial No.)	_____ (Filing Date)	_____ (Status-patented/pending/abandoned)
-------------------------------	------------------------	--

Power of Attorney

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Norman D. Hanson, Reg. No. 30,946; Andrew L. Tiajolloff, Reg. No. 31,575; John A. Bauer, Reg. No. 32,554; Mary Anne Schofield, Reg. No. 36,669; Madeline F. Baer, Reg. No. 36,437 and James R. Crawford, Reg. No. 39,155, my attorneys with full power of substitution and revocation. Address all telephone calls to Norman D. Hanson, at (212) 688-9200. Address all correspondence to:

FELFE & LYNCH
805 Third Avenue
New York, New York 10022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Matthew J. Scanlan

Full Name/Sole or First Inventor

Matthew Scanlan
Signature

JANUARY 14, 1998
Date

Residence: 1275 York Avenue

New York, New York 10021

U.S.A.
Citizenship

Post Office Address: Memorial Sloan-Kettering Cancer Center

1275 York Avenue, New York, New York 10021

(2) Yao-Tseng Chen

Full Name/Second Inventor

Signature

Date

Residence: 525 East 68th Street

New York, New York 10021

Taiwan
Citizenship

Post Office Address: 525 East 68th Street

New York, New York 10021

(3) Elisabeth Stockert

Full Name/Third Inventor

Elisabeth Stockert
Signature

JANUARY 14, 1998
Date

Residence: 1275 York Avenue

New York, New York 10021

AUSTRIA ~~U.S.A.~~

Citizenship

Post Office Address: Memorial Sloan-Kettering Cancer Center

1275 York Avenue, New York, New York 10021

(4) Lloyd J. Old

Full Name/Fourth Inventor

Lloyd J. Old
Signature

1/16/98
Date

Residence: 1345 Avenue of the Americas

New York, New York 10105

U.S.A.

Citizenship

Post Office Address: 1345 Avenue of the Americas

New York, New York 10105

Express Mail Label No:
EL024661754US
 Date of Deposit: 2-11-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Scanlan et al.
 Serial No.: 08/948,705
 Filed: October 10, 1997
 For: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH
 COLON CANCER AND METHODS FOR DIAGNOSING AND
 TREATING COLON CANCER
 Examiner: J.S. Brusca
 Art Unit: 1636

Assistant Commissioner for Patents
 Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

Sir:

The undersigned attorney has the power of attorney in the above-identified United States patent application, and hereby grants an associate power in the application to:


David Wolf	17,528	James H. Morris	34,681	John R. Van Amsterdam	40,212
George L. Greenfield	17,756	Peter C. Lando	34,684	Matthew B. Lowrie	38,228
Stanley Sacks	19,900	Gary S. Engelson	35,128	Michael G. Verga	39,410
Edward F. Perlman	28,105	Peter J. Gordon	35,164	Robert E. Rigby, Jr.	36,904
Lawrence M. Grach	29,384	Randy J. Pritsker	35,986	Robert A. Skrivaneck, Jr.	41,316
Steven J. Henry	27,900	Richard F. Giunta	36,149	Robert M. Abrahamson	40,886
Therese A. Hendricks	30,389	Douglas R. Wolf	36,971	Lesley A. Hamlin	41,054
Edward R. Gates	31,616	Elizabeth R. Plumer	36,637	Lindsay G. McGuinness	38,549
William R. McClellan	29,409	Timothy J. Oyer	36,628	Mike W. Crosby	40,970
Ronald J. Krasnagor	20,004	John N. Anastasi	37,765	Ivan D. Zitkovsky	37,482
M. Lawrence Oliveria	30,915	Helon C. Kindregan	39,248	Michale J. Young	P-43,299
James J. Foster	30,052	James M. Hanifin, Jr.	39,213	Edward J. Russavage	P-43,069
Charles E. Pfund	17,030	Christopher S. Schultz	37,929	Alan B. Sherx	P-42,147
Jason M. Honeyman	31,624	Paul D. Sorkin	39,039		

all of: Wolf, Greenfield & Sacks, P.C.,
 Federal Reserve Plaza
 600 Atlantic Avenue
 Boston, MA 02210-2211

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

By:


 Norman D. Hanson
 Reg. No. 30,946

805 Third Avenue
 New York, New York 10022
 (212) 688-9200
 Dated: July 13, 1998

*** TOTAL PAGE.03 ***

- 1 -

SEQUENCE LISTING

<110> Scanlan, Matthew J.
Chen, Yao-Tseng
Stockert, Elisabeth
Old, Lloyd J.

<120> ISOLATED NUCLEIC ACID MOLECULES
ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND
TREATING COLON CANCER

<130> LUD-5506-JEL/NDH

<140> US 08/948,705
<141> 1997-10-10

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 1552
<212> DNA
<213> Homo Sapiens

<400> 1

cttctggatg	catccgagaa	gctaaaactt	acttatgagg	aaaagtgtga	aattgaggaa	60
tcccaattga	agttttttgag	gaacgactta	gctgaatatc	agagaacttg	tgaagatctt	120
aaagagcaac	taaagcataa	agaattttctt	ctggctgcta	atacttgtaa	ccgtgttggt	180
ggtctttgtt	tgaaatgtgc	tcagcatgaa	gctgttcttt	cccaaaccga	tactaatgtt	240
catatgcaga	ccatcgaaaag	actggttaaa	gaaagagatg	acttgatgtc	tgcactagtt	300
tccgtaagga	gcagcttggc	agatacgag	caaagagaag	caagtgetta	tgaacagggtg	360
aaacaagttt	tgcaaataatc	tgaggaagcc	aattttgaaa	aaaccaaggc	tttaatccag	420
tgtgaccagt	tgaggaagga	gctggagagg	caggcggagc	gacttgaaaa	agaacttgca	480
tctcagcaag	agaaaagggc	cattgagaaa	gacatgatga	aaaaggaaat	aacgaaagaa	540
agggagtaca	tgggatcaaa	gatgttgatc	ttgtctcaga	atattgacca	actggaggcc	600
cagggtggaaa	agggttcaaaa	ggaaaagatt	tcagctatta	atcaactgga	ggaaattcaa	660
agccagctgg	cttctcgggg	aatggatgtc	acaaagggtgt	gtggagaaat	gcgctatcag	720
ctgaataaaa	ccaacatgga	gaaggatgag	gcagaaaagg	agcacaagga	gttcagagca	780
aaaactaaca	gggatcttga	aattaaagat	caggaaatag	agaaatcgag	aatagaactg	840
gatgaaagca	aacaacactt	ggaacaggag	cagcagaagg	cagccctggc	cagagaggag	900
tgcttgagac	taacagaact	gctgggagaa	tctgagcacc	aactgcacct	caccagatct	960
gaaatagctc	aactcagtca	agaaaaaagg	tatacatatg	ataaattggg	aaagttacag	1020
agaagaaatg	aagaattgga	ggaacagtgt	gtccagcatg	ggagagtaca	tgagacgatg	1080

	aagcaaggc	taaggcagct	ggataagcac	agccaggcca	cagcccagca	gctggtgcag	1140
	ctcctcagca	agcagaacca	gcttctcctg	gagaggcaga	gcctgtcgga	agagggtggac	1200
	cggctgcgga	cccagttacc	cagcatgcca	caatctgatt	gctgacctgg	atggaacaga	1260
	gtgaaataaa	tgaattacaa	agagatat	acattcatct	ggttttagact	taatatgcca	1320
5	caacgcacca	cgaccttccc	aggggtgacac	cgcctcagcc	tgcagtgggg	ctggctcctca	1380
	tcaacgcggg	cgctgtcccc	gcacgcagtc	gggctggagc	tggagtctga	ctctagctga	1440
	gcagactcct	ggtgtatgtt	ttcagaaatg	gcttgaagtt	atgtgtttaa	atctgctcat	1500
	tcgtatgcta	ggttatacat	atgattttca	ataaatgaac	tttttaaaga	aa	1552
10	<210> 2						
	<211> 2885						
	<212> DNA						
	<213> Homo Sapiens						
15	<400> 2						
	ggaattcctc	ttgtcgaagt	caaaggagcc	cacaccaggc	ggcctcaacc	attccctccc	60
	acagcacccc	aaatgctggg	gagcccacca	tgttctttg	gaccagagtt	cccctcccca	120
	gagcgcccc	cctgggacgc	ctccctccta	caaactgcct	ttgcctgggc	cctacgacag	180
	tcgagacgac	ttccccctcc	gcaaaacagc	ctctgaaccc	aacttgaaag	tgcgttcaag	240
20	gctaaaacag	aagggtggctg	agcggagaag	cagtcccctc	ctgcgtcgca	aggatgggac	300
	tgttattagc	acctttaaga	agagagctgt	tgagatcaca	ggtgccgggc	ctggggcgctc	360
	gtccgtgtgt	aacagcgcac	ccggctccgg	ccccagctct	cccaacagct	cccacagcac	420
	catcgctgag	aatggcttta	ctggctcagt	ccccaacatc	cccaactgaga	tgtccctca	480
	gcaccgagcc	ctccctctgg	acagctcccc	caaccagttc	agcctctaca	cgtctccttc	540
25	tctgccaac	atctccctag	ggctgcaggc	cacggtcact	gtcaccaact	cacacctcac	600
	tgctccccc	aagctgtcga	cacagcagga	ggccgagagg	caggccctcc	agtccctgcg	660
	gcagggtggc	acgctgaccg	gcaagttcat	gagcacatcc	tctattcctg	gctgcctgct	720
	gggctgtggc	ctggagggcg	acgggagccc	ccacgggcat	gcctccctgc	tgcagcatgt	780
	gctgttgctg	gagcaggccc	ggcagcagag	cacctcatt	gctgtgccac	tccacgggca	840
30	gtccccacta	gtgacgggtg	aacgtgtggc	caccagcatg	cggacggtag	gcaagctccc	900
	gcggcatcgg	cccctgagcc	gcactcagtc	ctcaccgctg	ccgcagagtc	cccaggccct	960
	gcagcagctg	gtcatgcaac	aacagcacca	gcagttcctg	gagaagcaga	agcagcagca	1020
	gctacagctg	ggcaagatcc	tcaccaagac	aggggagctg	cccaggcagc	ccaccaccca	1080
	ccctgaggag	acagaggagg	agctgacgga	gcagcaggag	gtcttgctgg	gggagggagc	1140
35	cctgaccatg	ccccgggagg	gctccacaga	gagtgagagc	acacaggaag	acctggagga	1200
	ggaggacgag	gaagaggatg	gggaggagga	ggaggattgc	atccaggtta	aggacgagga	1260
	gggcgagagt	ggtgctgagg	aggggcccga	cttgaggagg	cctggtgctg	gatacaaaaa	1320
	actgttctca	gatgcccaac	cgtgcaacc	tttgagggtg	taccaagcgc	ccctcagcct	1380
	ggccactgtg	ccccaccaag	ccctgggccc	tacctaatcc	tccctgctg	cccctggggg	1440
40	catgaagaac	ccccagacc	aaccgtcaa	gcacctcttc	accacaagtg	tggtctacga	1500
	cacgttcatg	ctaaagcacc	agtgcagtgt	cgggaacaca	cacgtgcacc	ctgagcatgc	1560
	tggccggatc	cagagcatct	ggtcccggct	gcaggagaca	ggcctgctta	gcaagtgcga	1620
	gcggatccga	ggtcgcaaag	ccacgctaga	tgagatccag	acagtgcact	ctgaatacca	1680
	cacctgctc	tatgggacca	gtccctcaa	ccggcagaag	ctagacagca	agaagttgct	1740
45	cggccccatc	agccagaaga	tgtatgctgt	gctgccttgt	gggggcacgc	gggtggacag	1800

	tgacaccgtg	tggaatgaga	tgcactcctc	cagtgcctgtg	cgcatggcag	tgggctgcct	1860
	gctggagctg	gccttcaagg	tggctgcagg	agagctcaag	aatggatttg	ccatcatccg	1920
	gccccagga	caccacgccg	aggaatccac	agccatggga	ttctgcttct	tcaactctgt	1980
	agccatcacc	gcaaaactcc	tacagcagaa	gttgaacgtg	ggcaagggtcc	tcacgtgga	2040
5	ctgggacatt	caccatggca	atggcaccca	gcaggcggtc	tacaatgacc	cctctgtgct	2100
	ctacatctct	ctgcatcgct	atgacaacgg	gaacttcttt	ccaggctctg	gggctcctga	2160
	agaggttggg	ggaggaccag	gcgtggggta	caatgtgaac	gtggcatgga	caggaggtgt	2220
	ggaccccccc	attggagacg	tggagtacct	tacagccttc	aggacagtgg	tgatgcccat	2280
	tgcccacgag	ttctcacctg	atgtggctct	agtctccgcc	gggtttgatg	ctgttgaagg	2340
10	acatctgtct	cctctgggtg	gtactctgt	caccgccaga	tgttttgcc	acttgaccag	2400
	gcagctgatg	accctggcag	ggggccgggt	ggtgctggcc	ctggaggag	gccatgactt	2460
	gaccgccatc	tgtgatgcct	ctgaagcttg	tgtctcggct	ctgctcagtg	taaagctgca	2520
	gcccttggtg	gaggcagtct	tgcagcaaaa	gccccaatc	aacgcagtgg	ccacgctaga	2580
	gaaagtcacg	gagatccaga	gcaaactctg	gagctgtgtg	cagaagtctg	ccgctggtct	2640
15	gggccggtcc	ctgcgagggg	cccaagcagg	tgagaccgaa	gaagccgaaa	tgtgaacgcc	2700
	atggccttgc	tgttggtggg	ggccgaacag	gccaagctg	cggcagcccg	ggaacacagc	2760
	cccaggccgg	cagaggagcc	catggagcag	gagcctgccc	tgtgacgccc	cggcccccat	2820
	ccctttgggc	ttcaccattg	tgattttggt	tattttttct	attaaaaaca	aaaagttaaa	2880
	aattt						2885

<210> 3

<211> 1298

<212> DNA

<213> Homo Sapiens

<220>

<221> unsure

<222> 55..55

<223>

<220>

<221> unsure

<222> 141..141

<223>

<220>

<221> unsure

<222> 199..99

<223>

<220>

<221> unsure

<222> 342..342

<223>

<220>
 <221> unsure
 <222> 352..352
 <223>

5

<220>
 <221> unsure
 <222> 722..722
 <223>

10

<220>
 <221> unsure
 <222> 750..750
 <223>

15

<220>
 <221> unsure
 <222> 1058..1058
 <223>

20

<220>
 <221> unsure
 <222> 1101..1101
 <223>

25

<220>
 <221> unsure
 <222> 1144..1144
 <223>

30

<400> 3

ggctgctgaa	atgactgcga	accggcttgc	agagagcctt	ctggctttga	gccancagga	60
agaactagcg	gatttgccaa	aagactacct	cttgagtgag	agtgaagatg	aggggggacaa	120
tgatggagag	agaaagcatc	naaagcttct	ggaagcaatc	agttcccttg	atggaaagaa	180
taggcggaaa	ttggctgana	ggtctgaggc	tagtctgaag	gtgtcagagt	tcaatgtcag	240
ttctgaagga	tcaggagaaa	agctggctct	tgcagatctg	cttgagcctg	ttaaaacttc	300
atcttctttg	gccactgtga	aaaagcaact	gagtagagtc	anatcaaaga	anacagtgga	360
gttacctctg	aacaaagaag	agattgaacg	gatccacaga	gaatagcatt	caataaaacg	420
cacaagtcct	ctccaaatgg	gaccctgtcg	tcctgaagaa	ccggcaggca	gagcagctgg	480
tttttccctt	ggagaaagag	gagccagcca	ttgtctccat	tgaacatgtg	ctcagtggct	540
ggaaggcaag	aactcccctg	gagcaggaaa	ttttcaacct	cctccataag	aacaagcagc	600
cagtgcacga	ccctttactg	accctgtggg	aaaaggcctc	tctccgagcc	atgagcctag	660
aagaggcaaa	gatgcgacga	gcagagcttc	agagggctcg	ggctctgcag	tcctactatg	720

	angccaaggc	tcgaagagag	aagaaaatcn	aaagttaaaa	gtatcacqaa	gtcgtgaaga	780
	aaggaaaggc	caagaaagcc	ctaaaagagt	ttgagcagct	gcggaagggt	aatccagctg	840
	ccgcactaga	agaacgaaga	aaagaggaaa	gaaggaggag	gagaaagaag	aagaacaagg	900
	agaagaagaa	agaagaaggg	agaaggagaa	gaaaagaagg	agaagaggaa	aaggaagaag	960
5	gagaaagaaa	aggagaagga	aaaggaaaag	aaggagaaga	aagaagaact	aagaagaagg	1020
	agaggaagaa	taagaaggaa	agaagaaaaga	aaaaagtnaa	agaagaagaa	agaaggaaga	1080
	aggaaaagaag	aggagaact	nagaagaaga	aagaggaggaa	aagaagaaaag	aagaataagg	1140
	aacnagaaag	aaggagaaga	aagaataaga	agaggaagaa	gaaaaagaag	aaaagaagaa	1200
	ggaaagaagg	agaaaaagga	agaaaaaagg	aagaagaaaag	tagaaagcgg	aagaaagaaa	1260
10	agaaagtata	agaaggaaga	agaagaaaaga	aggaaaaa			1298

<210> 4

<211> 2236

<212> DNA

15 <213> Homo Sapiens

<400> 4

	cctggcccgg	tcgcggtcgc	ggctctttcc	agctcctggc	agccgggcac	ccgaaggaac	60
	gggtcgtgca	acgacgcagc	tggacctggc	ccagccatgg	accgaaaagt	ggcccagagaa	120
20	ttccggcata	aggtggattt	tctgattgaa	aatgatgcag	agaaggacta	tctctatgat	180
	gtgctgcgaa	tgtaccacca	gaccatggac	gtggccgtgc	tcgtgggaga	cctgaagctg	240
	gtcatcaatg	aaccagccg	tctgcctctg	tttgatgcc	ttcggccgct	gatccactg	300
	aagcaccagg	tggaatatga	tcagctgacc	ccccggcgct	ccaggaagct	gaaggaggtg	360
	cgtctggacc	gtctgcacc	cgaaggcctc	ggcctgagtg	tgctgtgtgg	cctggagttt	420
25	ggctgtgggc	tcttcatctc	ccacctcatc	aaaggcggtc	aggcagacag	cgctggggctc	480
	caggtagggg	acgagatcgt	ccggatcaat	ggatattcca	tctcctcctg	tacccatgag	540
	gaggtcatca	acctcattcg	aaccaagaaa	actgtgtcca	tcaaagtgag	acacatcggc	600
	ctgatccccg	tgaaaagctc	tctgatgag	cccctcactt	ggcagtatgt	ggatcagttt	660
	gtgtcggaat	ctggggggcgt	gcgaggcagc	ctgggctccc	ctggaaatcg	ggaaaacaag	720
30	gagaagaagg	tcttcatcag	cctggtaggc	tcccgaggcc	ttggctgcag	catttccagc	780
	ggcccatcc	agaagcctgg	catctttatc	agccatgtga	aacctggctc	cctgtctgct	840
	gaggtgggat	tggagatagg	ggaccagatt	gtcgaagtca	atggcgtcga	cttctctaac	900
	ctggatcaca	aggaggctgt	aaatgtgctg	aaaaatagcc	gcagcctgac	catctccatt	960
	gtagctgcag	ctggccggga	gctgttcatg	acagaccggg	agcggctggc	agaggcgagg	1020
35	cagcgtgagc	tgcagcggca	ggagcttctc	atgcagaagc	ggctggcgat	ggagtccaac	1080
	aagatcctcc	aggagcagca	ggagatggag	cggcaaagga	gaaaagaaat	tgcccagaag	1140
	gcagcagagg	aaaatgagag	ataccggaag	gagatggaac	agattgtaga	ggaggaagag	1200
	aagtttaaga	agcaatggga	agaagactgg	ggctcaaagg	aacagctact	cttgccctaaa	1260
	accatcactg	ctgaggtaca	cccagtaccc	cttcgcaagc	caaagtatga	tcagggagtg	1320
40	gaacctgagc	tcgagcccg	agatgacctg	gatggaggca	cggaggagca	gggagagcag	1380
	gatttccgga	aatatgagga	aggctttgac	ccctactcta	tgttcacccc	agagcagatc	1440
	atggggaagg	atgtccggct	cctacgcac	aagaaggagg	gatccttaga	cctggccctg	1500
	gaaggcggtg	tggactcccc	cattgggaag	gtggctcggtt	ctgctgtgta	tgagcgggga	1560

	gctgctgagc	ggcatggtgg	cattgtgaaa	ggggacgaga	tcatggcaat	caacggcaag	1620
	attgtgacag	actacaccct	ggctgaggct	gacgctgccc	tgcagaaggc	ctggaatcag	1680
	ggcggggact	ggatcgacct	tgtggttgcc	gtctgcccc	caaaggagta	tgacgatgag	1740
	ctgaccttct	tgtgaagtc	caaaagggga	aaccaaattc	acgcgttagg	aaacagttag	1800
5	ctccggcccc	acctcgtgaa	cacaaagcct	cggaccagcc	ttgagagagg	ccacatgaca	1860
	cacaccagat	ggcatccttg	ggacctgaat	ctatcaccca	ggaatctcaa	actccctttg	1920
	gccctgaacc	agggccagat	aaggaacagc	tcggggccact	tttttgaagg	ccaatgtgga	1980
	ggaaagggag	cagccagccg	tttgggagaa	gatctcaagg	atccagactc	tcattccttt	2040
	cctctggccc	agtgaatttg	gtctctccca	gctttggggg	actccttctc	tgaaccctaa	2100
10	taagacccca	ctggagtctc	tctctctcca	tccctctcct	ctgccctctg	ctctaattgc	2160
	tgccaggatt	gtcactccaa	accttactct	gagctcatta	ataaaataaa	cagattttatt	2220
	ttccagctta	aaaaaa					2236

<210> 5

15 <211> 2162

<212> DNA

<213> Homo Sapiens

<400> 5

20	cctggccccg	tcgcggtcgc	ggctctttcc	agctcctggc	agccggggcac	ccgaagggaac	60
	gggtcgtgca	acgacgcagc	tggacctggc	ccagccatgg	accgaaaagt	ggccccgagaa	120
	ttccggcata	aggtggattt	tctgattgaa	aatgatgcag	agaaggacta	tctctatgat	180
	gtgctgcgaa	tgtaccacca	gaccatggac	gtggccgtgc	tcgtgggaga	cctgaagctg	240
	gtcatcaatg	aaccacagccg	tctgcctctg	tttgatgcc	ttcgcccgct	gatccactg	300
25	aagcaccagg	tggaaatatga	tcagctgacc	ccccggcgct	ccaggaagct	gaaggagggtg	360
	cgtctggacc	gtctgcaccc	cgaaggcctc	ggcctgagtg	tgcgtggtgg	cctggagttt	420
	ggctgtgggc	tcttcatctc	ccacctcatc	aaaggcggtc	aggcagacag	cgtcgggctc	480
	caggtagggg	acgagatcgt	ccggatcaat	ggatattcca	tctcctctctg	tacccatgag	540
	gaggtcatca	acctcattcg	aaccaagaaa	actgtgtcca	tcaaagttag	acacatcggc	600
30	ctgatccccg	tgaaaagctc	tctgatgag	cccctcactt	ggcagtatgt	ggatcagttt	660
	gtgtcggaat	ctggggggcgt	gcgaggcagc	ctgggctccc	ctggaaatcg	ggaaaacaag	720
	gagaagaagg	tcttcatcag	cctggtaggc	tcccagggcc	ttggctgcag	cattttccagc	780
	ggccccatcc	agaagcctgg	catctttatc	agccatgtga	aacctggctc	cctgtctgct	840
	gaggtgggat	tggagatagg	ggaccagatt	gtcgaagtca	atggcgtcga	cttctctaac	900
35	ctggatcaca	aggaggctgt	aaatgtgctg	aaaaatagcc	gcagcctgac	catctccatt	960
	gtagctgcag	ctggccggga	gctgttcatg	acagaccggg	agcggtggc	agaggcgcg	1020
	cagcgtgagc	tgcagcggca	ggagcttctc	atgcagaagc	ggctggcgat	ggagtccaac	1080
	aagatcctcc	aggagcagca	ggagatggag	cggcaaagga	gaaaagaaat	tgcccagaag	1140
	gcagcagagg	aaaatgagag	ataccggaag	gagatggaac	agattgtaga	ggaggaagag	1200
40	aagtttaaga	agcaatggga	agaagactgg	ggctcaaagg	aacagctact	cttgccctaaa	1260
	accatcactg	ctgaggtaca	cccagtaccc	cttcgcaagc	caaagtgatt	tccggaaata	1320
	tgaggaaggc	tttgaccct	actctatgtt	caccacagag	cagatcatgg	ggaaggatgt	1380
	ccggctccta	cgcacaaaga	aggagggatc	cttagacctg	gccctggaag	gcggtgtgga	1440

CCF20" 44620550

	ctccccatt	gggaaggtgg	togtttctgc	tgtgtatgag	cggggagctg	ctgagcggca	1500
	tgggtggcatt	gtgaaagggg	acgagatcat	ggcaatcaac	ggcaagattg	tgacagacta	1560
	caccttggt	gaggtgacg	ctgccctgca	gaaggcctgg	aatcagggcg	gggactggat	1620
	cgaccttggt	gttgccgtct	gcccccaaa	ggagtatgac	gatgagctga	ccttcttgct	1680
5	gaagtcctaaa	aggggaaacc	aaattcacgc	gttaggaaac	agtgagctcc	ggccccacct	1740
	cgtgaacaca	aagcctcgga	ccagccttga	gagaggccac	atgacacaca	ccagatggca	1800
	tccttgggac	ctgaatctat	caccacaggaa	tctcaaactc	cctttggccc	tgaaccaggg	1860
	ccagataagg	aacagctcgg	gccacttttt	tgaaggccaa	tgtggaggaa	agggagcagc	1920
	cagccgtttg	ggagaagatc	tcaaggatcc	agactctcat	tcctttcttc	tggcccgagt	1980
10	aattttggtct	ctcccagctt	tgggggactc	cttccttgaa	ccctaataag	acccccactgg	2040
	agtctctctc	tctccatccc	tctcctctgc	cctctgctct	aattgctgcc	aggattgtca	2100
	ctccaaacct	tactctgagc	tcattaataa	aataaacaga	tttattttcc	agcttaaaaa	2160
	aa						2162
15	<210> 6						
	<211> 1789						
	<212> DNA						
	<213> Homo Sapiens						
20	<400> 6						
	cttctggatg	catccgagaa	gctaaaactt	acttatgagg	aaaagtgtga	aattgaggaa	60
	tcccaattga	agtttttgag	gaacgactta	gctgaatata	agagaacttg	tgaagatctt	120
	aaagagcaac	taaagcataa	agaatttctt	ctggctgcta	atacttgtaa	ccgtgttggt	180
	ggctcttggt	tgaatgtgc	tcagcatgaa	gctgttcttt	cccaaaccga	tactaatgtt	240
25	catatgcaga	ccatcgaaag	actgggttaa	gaaagagatg	acttgatgtc	tgcactagtt	300
	tccgtaagga	gcagcttggc	agatacgag	caaagagaag	caagtgttta	tgaacagggt	360
	aaacaagttt	tgcaaatata	tgagggaagg	aattttgaaa	aaaccaaggc	tttaattccag	420
	tgtgaccagt	tgagggaagg	gctggagagg	caggcggagc	gacttgaaaa	agaacttgca	480
	tctcagcaag	agaaaagggc	cattgagaaa	gacatgatga	aaaaggaaat	aacgaaaaga	540
30	agggagtaca	tgggatcaaa	gatgttgatc	ttgtctcaga	atattgcccc	actggaggcc	600
	caggtggaaa	aggttacaaa	ggaaaagatt	tcagctatta	atcaactgga	ggaaattcaa	660
	agccagctgg	cttctcgga	aatggatgtc	acaaagggtg	gtggagaaat	gcgctatcag	720
	ctgaataaaa	ccaacatgga	gaaggatgag	gcagaaaagg	agcacagaga	gttcagagca	780
	aaaactaaca	gggatcttga	aattaaagat	caggaaatag	agaaattgag	aatagaactg	840
35	gatgaaagca	aacaacactt	ggaacaggag	cagcagaagg	cagccctggc	cagagaggag	900
	tgcttgagac	taacagaact	gctgggcgaa	tctgagcacc	aactgcacct	caccagacag	960
	gaaaaagata	gcattcagca	gagcttttag	aagggaagcaa	aggcccaagc	ccttcaggcc	1020
	cagcaaagag	agcaggagct	gacacagaag	atacagcaaa	tgggaagcca	gcatgacaaa	1080
	actgaaaatg	aacagtattt	gttgctgacc	tcccagaata	catttttgac	aaagttaaa	1140
40	gaagaatgct	gtacattagc	caagaaactg	gaacaaatct	ctcaaaaaac	cagatctgaa	1200
	atagctcaac	tcagtcaaga	aaaaaggat	acatatgata	aattgggaaa	gttacagaga	1260
	agaaatgaag	aattggagga	acagtgtgtc	cagcatggga	gagtacatga	gacgatgaag	1320
	caaaggctaa	ggcagctgga	taagcacagc	caggccacag	cccagcagct	ggtgcagctc	1380

	ctcagcaagc	agaaccagct	tctcctggag	aggcagagcc	tgtcgggaaga	ggtggaccgg	1440
	ctgcggaacc	agttacccag	catgccacaa	tctgattgct	gacctggatg	gaacagagtg	1500
	aaataaatga	attacaaaga	gatattttaca	ttcatctggg	ttagacttaa	tatgccacaa	1560
	cgcaccacga	ccttcccagg	gtgacaccgc	ctcagcctgc	agtggggctg	gtcctcatca	1620
5	acgcggggcg	tgtccccgca	cgcagtcggg	ctggagctgg	agtctgactc	tagctgagca	1680
	gactcctggg	gtatgttttc	agaaatggct	tgaagttatg	tgtttaaatc	tgctcattcg	1740
	tatgctaggt	tatacatatg	attttcaata	aatgaacttt	ttaaagaaa		1789

<210> 7

10 <211> 1306

<212> DNA

<213> Homo Sapiens

<400> 7

15	aaaaatagcc	gcagcctgac	catctccatt	gtagctgcag	ctggccggga	gctgttcatg	60
	acagaccggg	agcggctggc	agaggcgagg	cagcgtgagc	tgcagcggca	ggagcttctc	120
	atgcagaagc	ggctggcgat	ggagtccaac	aagatcctcc	aggagcagca	ggagatggag	180
	cggcaaagga	gaaaagaaat	tgcccagaag	gcagcagagg	aaaatgagag	ataccggaag	240
	gagatggaac	agattgtaga	ggagggaagag	aagttaaaga	agcaatggga	agaagactgg	300
20	ggctcaaagg	aacagctact	cttgcctaaa	accatcactg	ctgaggtaca	cccagtacct	360
	cttcgcaagc	caaagtatga	tcagggagtg	gaacctgagc	tcgagcccg	agatgacctg	420
	gatggaggca	cggaggagca	gggagagcag	gatttccgga	aatatgagga	aggctttgac	480
	ccctactcta	tgttcacccc	agagcagatc	atggggaagg	atgtccggct	cctacgcac	540
	aagaaggagg	gacccctaga	cctggccctg	gaaggcgggt	tggactcccc	cattgggaag	600
25	gtggctcggt	ctgctgtgta	tgagcgggga	gctgctgagc	ggcatgggtg	cattgtgaaa	660
	ggggacgaga	tcattggcaat	caacggcaag	attgtgacag	actacaccct	ggctgaggct	720
	gacgtgccc	tgcagaaggc	ctggaatcag	ggcggggact	ggatcgacct	tgtggttgcc	780
	gtctgcccc	caaaggagta	tgacgatgag	ctgaccttct	tgtgaagtc	caaaagggga	840
	aaccaaattc	acgcgttagg	aaacagttag	ctccggcccc	acctcgtgaa	cacaaagcct	900
30	cggaccagcc	ttgagagagg	ccacatgaca	cacaccagat	ggcatccttg	ggacctgaat	960
	ctatcaccca	ggaatctcaa	actccctttg	gccctgaacc	agggccagat	aaggaacagc	1020
	tcggggccact	tttttgaagg	ccaatgtgga	ggaaagggag	cagccagccg	tttgggagaa	1080
	gatctcaagg	atccagactc	tcattccttt	cctctggccc	agtgaatttg	gtctctccca	1140
	gctttggggg	actccttctc	tgaaccctaa	taagacccca	ctggagtctc	tctctctcca	1200
35	tccctctcct	ctgccctctg	ctctaattgc	tgccaggatt	gtcactccaa	accttactct	1260
	gagctcatta	ataaaaataaa	cagattttatt	ttccagctta	aaaaaa		1306

<210> 8

<211> 2289

40 <212> DNA

<213> Homo Sapiens

<400> 8

00120 54620560

	cctggcccg	tcgcggtcgc	ggctctttcc	agctcctggc	agccgggcac	ccgaaggaac	60
	gggtcgtgca	acgacgcagc	tggacctggc	ccagccatgg	accgaaaagt	ggccccgagaa	120
	ttccggcata	aggtggattt	tctgattgaa	aatgatgcag	agaaggacta	tctctatgat	180
	gtgctgcgaa	tgtaccacca	gaccatggac	gtggccgtgc	tcgtgggaga	cctgaagctg	240
5	gtcatcaatg	aaccagccg	tctgcctctg	tttgatgcc	ttcgcccgct	gatccactg	300
	aagcaccagg	tggaatatga	tcagctgacc	ccccggcgct	ccaggaagct	gaaggaggtg	360
	cgtctggacc	gtctgcaccc	cgaaggcctc	ggcctgagtg	tgcgtggtgg	cctggagttt	420
	ggctgtgggc	tcttcatctc	ccacctcatc	aaaggcggtc	aggcagacag	cgtcgggctc	480
	caggtagggg	acgagatcgt	ccggatcaat	ggatattcca	tctcctcctg	tacccatgag	540
10	gaggtcatca	acctcattcg	aaccaagaaa	actgtgtcca	tcaaagttag	acacatcggc	600
	ctgatccccg	tgaagaagtc	tctgatgag	ccccctactt	ggcagtatgt	ggatcagttt	660
	gtgtcggaat	ctggggggcgt	gcgaggcagc	ctgggctccc	ctggaaatcg	ggaaaacaag	720
	gagaagaagg	tcttcatcag	cctggtaggc	ttccgaggcc	ttggctgcag	catttccagc	780
	ggccccatcc	agaagcctgg	catctttatc	agccatgtga	aacctggctc	cctgtctgct	840
15	gaggtgggat	tggagatagg	ggaccagatt	gtcgaagtca	atggcgctga	cttctctaac	900
	ctggatcaca	aggaggctgt	aaatgtgctg	aaaaatagcc	gcagcctgac	catctccatt	960
	gtagctgcag	ctggccggga	gctgttcatg	acagaccggg	agcggtggc	agaggcgagg	1020
	cagcgtgagc	tgcagcggca	ggagcttctc	atgcagaagc	ggctggcgat	ggagtccaac	1080
	aagatcctcc	aggagcagca	ggagatggag	cggcaaagga	gaaaagaaat	tgcccagaag	1140
20	gcagcagagg	aaaatgagag	ataccggaag	gagatggaac	agattgtaga	ggaggaagag	1200
	aagtttaaga	agcaatggga	agaagactgg	ggctcaaagg	aacagctact	cttgcctaaa	1260
	accatcactg	ctgaggtaca	cccagtacct	cttcgcaagc	caaagtatga	tcagggagtg	1320
	gaacctgagc	tcgagcccg	agatgacctg	gatggaggca	cggaggagca	gggagagcag	1380
	ccacaggaga	tgttgaagag	gatggtggtt	tatcaagaca	gcattcaaga	caagatttcc	1440
25	ggaaatatga	ggaaggcttt	gacctctact	ctatgttcac	cccagagcag	atcatgggga	1500
	aggatgtccg	gctcctacgc	atcaagaagg	agggatcctt	agacctggcc	ctggaaggcg	1560
	gtgtggactc	ccccattggg	aagggtggtc	tttctgctgt	gtatgagcgg	ggagctgctg	1620
	agcggcatgg	tggcattgtg	aaaggggacg	agatcatggc	aatcaacggc	aagattgtga	1680
	cagactacac	cctggctgag	gctgacgctg	ccctgcagaa	ggcctggaat	cagggcgggg	1740
30	actggatcga	ccttgtggtt	gccgtctgcc	ccccaaagga	gtatgacgat	gagctgacct	1800
	tcttgtctgaa	gtccaaaagg	ggaaaccaa	ttcacgcgtt	aggaaacagt	gagctccggc	1860
	cccacctcgt	gaacacaaag	cctcggacca	gccttgagag	aggccacatg	acacacacca	1920
	gatggcatcc	ttgggacctg	aatctatcac	ccaggaatct	caaactccct	ttggccctga	1980
	accagggcca	gataaggaac	agctcggggc	acttttttga	aggccaatgt	ggaggaaagg	2040
35	gagcagccag	ccgtttggga	gaagatctca	aggatccaga	ctctcattcc	tttctctctg	2100
	cccagtgaat	ttggtctctc	ccagctttgg	gggactcctt	ccttgaacct	taataagacc	2160
	ccactggagt	ctctctctct	ccatccctct	cctctgccct	ctgctcta	tgctgccagg	2220
	attgtcactc	caaacccttac	tctgagctca	ttaataaaat	aaacagattt	attttccagc	2280
	ttaaaaaaa						2289

40